Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ticagrelor - AstraZeneca

Drug Profile

Ticagrelor - AstraZeneca

Alternative Names: AR-C-126532; AZD-6140; Brilinta; Brilique

Latest Information Update: 25 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; The Medicines Company; Uppsala University; Vanderbilt University
  • Class Antianaemics; Antibacterials; Antithrombotics; Cardiovascular therapies; Cyclopropanes; Fluorobenzenes; Purine nucleosides; Ribonucleosides; Small molecules; Vascular disorder therapies
  • Mechanism of Action Platelet ADP receptor antagonists; Purinoceptor P2Y12 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute coronary syndromes
  • Phase III Cardiovascular disorders; Sickle cell anaemia; Stroke
  • Phase II Abdominal aortic aneurysm; Community-acquired pneumonia; Coronary artery disease
  • Discontinued Peripheral arterial disorders

Most Recent Events

  • 02 Sep 2019 Efficacy and adverse events data from the phase III THEMIS trial in Cardiovascular disorders released by AstraZeneca
  • 26 Aug 2019 Region Skane in collaboration with AstraZeneca plans the phase III AUGEAS trial for Coronary Artery Disease in diabetes mellitus patients (NCT04069234)
  • 07 May 2019 AstraZeneca completes the phase I HESTIA4 trial in Sickle cell anaemia (In infants) in United Kingdom, Lebanon, Spain, Kenya, Italy, Belgium (PO) (NCT03492931)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top